Dimethylamine

Dimethylamine

SCHEMBL6950205

CCCCN1CCC(=NO)CC1.CNC

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.40
ALDH1A1 P00352 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GLB1 P16278 1/20 0.35
SIGMAR1 Q99720 4/20 0.35
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
OPRK1 P41145 1/20 0.35
GNAI3 P08754 1/20 0.34
GNAO1 P09471 1/20 0.34
GNAI1 P63096 1/20 0.34
S1PR1 P21453 1/20 0.34
S1PR3 Q99500 1/20 0.34
S1PR5 Q9H228 1/20 0.34
OGG1 O15527 1/20 0.34
EBP Q15125 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylamine SCHEMBL8115201 1.00 CHRNA7 (0.40) CHRNA7ALDH1A1CYP1A2CYP2D6CYP2C19
Dimethylamine SCHEMBL6941904 0.95 GNAI3 (0.41) CHRNA7GNAI3GNAO1GNAI1S1PR1
SCHEMBL6942014 0.94 CHRNA7 (0.44) CHRNA7ALDH1A1CYP2D6GLB1SIGMAR1
SCHEMBL8108441 0.94 CHRNA7 (0.44) CHRNA7ALDH1A1CYP2D6GLB1SIGMAR1
Methylamine SCHEMBL7228187 0.91 CHRNA7 (0.41) CHRNA7ALDH1A1CYP2D6GLB1SIGMAR1
Diethylamine SCHEMBL6941485 0.90 CHRNA7 (0.38) CHRNA7ALDH1A1CYP1A2CYP2D6CYP2C19
Dimethylamine SCHEMBL6948503 0.89 ALDH1A1 (0.43) CHRNA7ALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL6939508 0.88 CHRNA7 (0.37) CHRNA7ALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL6941816 0.88 CHRNA7 (0.37) CHRNA7ALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL8099579 0.88 CHRNA7 (0.37) CHRNA7ALDH1A1CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642231-B2 Antineoplastic agents, treatment for neuronal injury and degeneration AVENTIS PHARMACEUTICALS INC. 2003-11-04 US disclosed
EP-1056744-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2003-10-22 EP disclosed
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines AVENTISUB II INC. 2003-06-05 US disclosed
US-6479487-B1 INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS AVENTIS PHARMACEUTICALS INC. 2002-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines CDK6, CDK5, CDK2 CHRNA7 3390/4885ALDH1A1 2147/4885CYP1A2 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.